Presenter: Israel Gasperin, Founder and CEO of Zentrela.

Title: Neurotechnology for measuring cannabis product effects

Abstract: After 5 years of full R&D and scientific validation, Zentrela has developed the first test for measuring cannabis effects based on brainwave analysis and AI, called Cognalyzer®. In the absence of neurotechnology like the Cognalyzer®, current drug tests attempted to measure cannabis impairment by quantifying concentration levels of THC in body fluids (blood, urine, saliva, etc.) and determining a threshold. This method is still very useful to detect with high accuracy if a subject consumed cannabis recently but it is very challenging to determine actual cannabis impairment due the lack of direct relationship between THC levels in body fluids and actual THC’s psychoactive effects on the brain.

Please register here via Eventbrite. *For more information: Please contact yaserk@yorku.ca